

Retrograde Ascending Dissection: Intraluminal Aortic Therapy

NCT07405242

Status	RECRUITING
Phase	Not Applicable
Sponsor	Ruijin Hospital
Enrollment	149 participants

Key Eligibility Criteria

Inclusion (5)

- Voluntary participation in the clinical trial; The individual fully understands and is informed of this study and has signed the informed consent form; Willing to follow and be able to complete all trial procedures
- Age ≥ 65 years old, both male and female are eligible
- Confirmed by imaging to be retrograde tear aortic dissection, that is, the tear site is located at the aortic arch or descending aorta, and the retrograde tear involves the ascending aorta. The farthest segment of the dissection tear is ≤ 2 cm from the coronary artery outlet
- Evaluation by cardiac surgery indicates that open surgical treatment is not suitable, performing open surgery poses significant risks or the risks outweigh the benefits
- Arterial access conditions are permitted, without severe stenosis or distortion, and the stent delivery system can be smoothly introduced;

Exclusion (12)

- Severe organ ischemia or functional failure, which, after assessment, is considered to have an extremely poor prognosis and cannot benefit from endovascular treatment, such as extensive cerebral infarction or cerebral hemorrhage, resulting in irreversible severe neurological deficits, acute extensive ischemic necrosis of the mesenteric arteries, acute liver and kidney failure;
- Planned to undergo aortic valve repair/replacement or coronary artery interventional therapy within 30 days;
- Mechanical heart valve present at the aortic valve position;
- Aortic valve regurgitation degree ≥ 3+ or 4+;
- Known severe allergy to contrast agents or stent materials (such as nickel-titanium alloys, polyester, etc.);
- ... and 7 more (see full listing online)

Locations (1 total)

Shanghai Jiao Tong University Medical School Affiliated Ruijing Hospital, Shanghai, Shanghai Municipality, China